Literature DB >> 9517965

Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin.

M E Evans, W B Titlow.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9517965      PMCID： PMC105531     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  2 in total

1.  In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191
  2 in total
  7 in total

1.  Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.

Authors:  Michele Pohlen; Julia Marx; Alexander Mellmann; Karsten Becker; Rolf M Mesters; Jan-Henrik Mikesch; Christoph Schliemann; Georg Lenz; Carsten Müller-Tidow; Thomas Büchner; Utz Krug; Matthias Stelljes; Helge Karch; Georg Peters; Hans U Gerth; Dennis Görlich; Wolfgang E Berdel
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

2.  Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.

Authors:  T D Gootz; R P Zaniewski; S L Haskell; F S Kaczmarek; A E Maurice
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Low frequencies of resistance among Staphylococcus and Enterococcus species to the bactericidal DNA polymerase inhibitor N(3)-hydroxybutyl 6-(3'-ethyl-4'-methylanilino) uracil.

Authors:  Michelle M Butler; Donna J Skow; Ryan O Stephenson; Patrick T Lyden; William A LaMarr; Kimberly A Foster
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

4.  Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Patrice Francois; Carmelo Bisognano; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.

Authors:  Jeffrey J Campion; Patrick J McNamara; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.

Authors:  Michelle M Butler; William A Lamarr; Kimberly A Foster; Marjorie H Barnes; Donna J Skow; Patrick T Lyden; Lauren M Kustigian; Chengxin Zhi; Neal C Brown; George E Wright; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

Review 7.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.